Invivyd, Inc. (NASDAQ:IVVD)
| Market Cap | 168.72M-62.3% |
| Revenue (ttm) | 58.37M+26.3% |
| Net Income | -107.33M+2.5% |
| EPS | -0.39+57.1% |
| Shares Out | 294.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,140,886 |
| Open | 0.64 |
| Previous Close | 0.63 |
| Day's Range | 0.56 - 0.64 |
| 52-Week Range | 0.53 - 3.07 |
| Beta | 0.71 |
| Analysts | Buy |
| Price Target | 9.50(+1559.68%) |
| Earnings Date | Nov 5, 2026 |
0 qualifying trades · 0 insiders · $0 bought in the last 90 days
Invivyd, Inc. Stock Analysis — InsiderScore
See top-rated InsiderScore stocks ›Invivyd, Inc. scored higher than 24% of companies evaluated by InsiderBuying, and ranked 185th out of 321 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Invivyd, Inc. lost 30.0 points for growing its share count over the trailing twelve months. Growth under 5% costs nothing; above 25% takes the full 30-point penalty. Insiders buying while the company issues stock to everyone else is a weaker signal than insiders buying a fixed pie.
About IVVD
Invivyd, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Invivyd maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating IVVD in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 5, 2026Earnings report
Ask Barron about IVVD
$IVVD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IVVD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IVVD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IVVD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IVVD Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| VYD2311 | $20.35M | 85.68% |
| Other income, net | $1.43M | 6.01% |
| Cost of product revenue | $1.27M | 5.36% |
| Pemivibart | $265.00K | 1.12% |
| VMS063 | $182.00K | 0.77% |
| Early-stage programs | $175.00K | 0.74% |
| VBY329 | $80.00K | 0.34% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IVVD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IVVD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IVVD
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $6.77M |
| IWMiShares Russell 2000 ETF | $3.63M |
| VXFVanguard Extended Market ETF | $2.54M |
| IWNiShares Russell 2000 Value ETF | $1.28M |
| VTWOVanguard Russell 2000 ETF | $1.11M |
| IWCiShares Micro-Cap ETF | $416.79K |
Estimated from each fund’s disclosed top holdings × AUM
IVVD Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IVVD’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: 114 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 42.8
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-42.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.